Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Techniclone (TCLN) -- Ignore unavailable to you. Want to Upgrade?

To: Terry D. who wrote (2802)	12/18/1998 2:15:00 PM
From: stockwiz	Respond to of 3702

To:Loyal Cloners From Stockwiz I think the time is at hand for this little company with big ideas.I,ve been watching from a distance and keeping up with the posts as well as checked my contacts and I feel good things are about to happen for all of us. Happy Holidays to all and best wishes. Stockwiz

To: Terry D. who wrote (2802)	12/18/1998 3:45:00 PM
From: Maurice Winn	Read Replies (1) \| Respond to of 3702

Terry, I agree. A rights issue is what I've suggested from time to time most of this year. But TCLN, about April, offered me and other investors a bunch of shares at a 15% discount but with pages of details, warrants and verbosity. The deal should be straight and clean. Here are some $1 shares offered to existing shareholders who may sell the right to buy those shares if they don't want or can't afford them. No mucking around, no big deal paperwork needing fancy legalese. No dilution. No muss, no fuss. Maurice *Warning - click 'next' - Reverse split comment* PS: Robert, sure, companies with good fundamentals wouldn't usually be interested in reverse splits, but companies with good fundamentals who end up with a low share price - say 50 cents a share, could benefit by being listed etc. You can have good fundamentals but a low share price simply by an excellent idea taking a LOT more time and money than expected. Sure you can stay delisted and out of sight, but hiding your light under a bushel is not a good marketing strategy and companies should be selling themselves to maximize shareholder value. It's tempting to think that a company wouldn't have a low share price if they have good fundamentals. Well, you don't need to be around markets for long to realize that some major bargains were very cheap maybe 4 years before. IDEC was only $2 a couple of years ago - now $45 or so. Hopefully TCLN will go from $1 to $20 if Oncolym and TNT turn out fine. Then zoom more if the other products also work out. Right now things seem okay with the share price on the screen. Since time is going by and Oncolym is getting closer to being a real product with passable clinical outcomes, maybe there won't be a slip back to unlisted territory. I've now been watching TCLN for a year and what a down and up year it has been. Not all that much progress but in the right direction. Other than the two who snuck in below my $4 1 Jan 1999 guess, I was the closest! In fact, are those two still around to collect the winner's trip to Aruba? Maybe I get it by default? Could yet be the closest, though not likely.